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Renal cell carcinoma is the most deadly of common urologic malignancies. The clas- 
sical prognostic factors, including tumor type, grade and stage, as well as perfor-
mance status of the patient, offer important information, but there is a need for 
new biomarkers which could improve the quality of prognostication. It has been 
proposed that tumors co-expressing P53 and MDM2 could represent a specific, 
more aggressive subgroup. The aim of the study was to explore this hypothesis 
using tissue microarrays, using two different anti-P53 antibodies. The material 
analyzed consisted of 470 cases of renal clear cell carcinoma. Reaction for P53 
was positive in 15.1 or 13.2% of cases, depending on the antibody used. Reaction 
for MDM2 was positive in 37.9% of cases; 6.5 or 5.3% of cases coexpressed P53 
and MDM2. Both P53-positive and double P53/MDM2-positive cases were higher 
grade and more likely to contain a sarcomatoid component, but their stage was 
similar to negative cases. PAb1081 P53-positive MDM2-positive cases were larger 
than the rest of the tumors (7.6 cm vs. 6.1 cm, p < 0.001). Our data support the 
hypothesis of prognostic significance of P53, and double P53/MDM2 positivity, yet 
further studies are needed to clarify the issue.
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Introduction
Renal cell carcinoma (RCC) constitutes approxi-
mately 9% of human cancers and is the most deadly 
of urological malignancies. Recently, interest in the 
biology of RCC, especially its most frequent variant 
clear cell RCC (CCRCC), has increased considerably. 
This increased interest is partly due to the introduc-
tion of new methods of treatment, such as target-
ed drugs or alternative surgery. Prognostic factors 
of CCRCC include stage, grade and histologic type; 
many biomarkers have been studied, but few of them 
have yet become of any practical importance [1, 2].
TP53, possibly the best known tumor suppressor 
gene, is mutated in over 50% of human cancers, and 
in some cases (e.g. high grade urothelial carcinoma, 
high grade serous ovarian carcinoma) is the main 
driving force behind this neoplastic process. Tumors 
bearing TP53 mutation usually express detectable 
amounts of P53 protein; immunohistochemistry is 
thus often used as a surrogate for direct detection of 
TP53 mutation. The mutation of TP53, however, is 
not the only mechanism leading to increased P53 ex-
pression. In CCRCC, TP53 mutation is much less fre-
quent; however, P53 expression is detectable at the 
histochemical level [3]. The significance of the latter 
observation in CCRCC remains controversial. It has 
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been proposed that CCRCCs co-expressing P53 and 
MDM2 may constitute a distinct, more aggressive 
group of CCRCCs [4-6]. The aim of this study was to 
compare the P53/MDM2-positive carcinomas with 
all other CCRCCs in regard to their basic morpho-
logic features known to influence prognosis. In addi-
tion, the use of two different P53-specific antibodies 
allowed for a more in-depth look at expression and 
co-expression patterns in the tumor material studied.
Material and methods
The material studied was retrieved from the De-
partment of Pathomorphology archives. Cases were 
reviewed by an expert urologic pathologist and re-
classified according to the most recent WHO classi-
fication [7]. For the present study, only unequivocal 
conventional (clear cell) carcinomas were chosen. The 
tumors were graded according to the International 
Society of Urological Pathologists, which uses a mod-
ification of the Fuhrman method [8], referred to as 
the Fuhrman method from this point forward. The 
presence of sarcomatoid components and necrosis 
was observed, and in accordance with Delahunt et 
al. [9], tumor grade that took necrosis into consider-
ation was assigned.
For each case, a slide containing well-preserved and 
representative tumor tissue was selected and a respec-
tive area was marked for study. Corresponding blocks 
were used to construct a tissue microarray (TMA) us-
ing Tissue MicroArrayer MTA-1 (Beecher Instruments 
Inc., Sun Prairie, USA). From each donor block, three 
0.6 mm cylinders were selected. The acceptor paraffin 
blocks were prepared noting the location of each cyl-
inder, and 3-µm thick sections were cut.
For immunohistochemistry, a standard staining 
protocol was used. Briefly, the slides were dewaxed, 
rehydrated and incubated in 3% peroxide solution for 
10 minutes to block endogenous peroxidase activity. 
Antigen retrieval was carried out by microwaving in 
citrate buffer (0.2% citric acid titrated to pH 6.0 with 
2N NaOH) 3 times for 5 minutes each at 750 W. 
The primary antibodies are listed in Table I. The Lab 
Vision detection system (Thermo Fisher Scientific, 
Waltham, USA) was used. The chromogen used was 
3-amino-9-ethylcarbazole. The slides were counter- 
stained with Mayer hematoxylin (Thermo Fisher Sci-
entific, Waltham, USA) and coverslipped. The cas-
es were classified as positive or negative by one of 
the authors (M.H.) without knowledge of the clin-
icopathologic parameters and the results of scoring 
were introduced into an Excel spreadsheet (Microsoft 
Corp., Redmond, USA). Cases lost from the TMAs 
were excluded from the study. Student t-statistics, 
c2 and ANOVA tests were used when appropriate. 
Correlations were measured by Pearson’s and gam-
ma correlation coefficients. The statistical analysis 
was done with Statistica 10 PL (StatSoft Inc., Tulsa, 
USA) and P values less than 0.05 were considered 
significant.
Results
The material under study was obtained from 470 
cases of CCRCC. There were 280 (59.6%) males and 
190 (40.4%) females. The mean age was 61.3 years 
(range 26 to 92; SD 10.59). Females in this group 
were slightly older than males (62.3 vs. 60.7) yet this 
was not statistically significant. In 200 cases (42.6%) 
the tumor was stage pT1, in 41 cases (8.7%) pT2, in 
223 cases (47.4%) pT3 and in 3 cases (0.6%) pT4, 
while in 3 cases (0.6%) no information about the 
stage was available. The average diameter of the le-
sions was 6.2 cm (range 0.8 to 26 cm, SD 3.3) and 
the size of the tumors in both sexes was very similar 
(6.3 cm in females versus 6.2 cm in males, p > 0.05). 
At presentation, 5 cases showed lymph node metas-
tases and 2 additional distant metastases. Because of 
the low number of such cases, metastatic disease is 
not analyzed in detail in this manuscript.
A sarcomatoid component was present in 29 cases 
(6.2%). Fuhrman grade was G1 in 140 cases (29.8%), 
G2 in 169 cases (36%), G3 in 112 cases (23.8%) and 
G4 in 49 cases (10.4%). Necrosis was present in 109 
cases (23.2%). Tumor grade according to Delahunt et 
al. [9] was G1 in 283 cases (60.2%), G2 in 91 cases 
(19.4%), G3 in 54 cases (11.5%) and G4 in 42 cases 
(8.9%).
A positive reaction for P53 using the PAb1081 an-
tibody was observed in 62 cases (13.2%). Reaction 
for P53 using the DO-7 antibody was positive in 71 
cases (15.1%). The relationship between these two 
reactions is shown in Table II. Reaction for MDM2 
was positive in 178 cases (37.9%). The relationship 
between P53 and MDM2 stains is shown in Table III.
Table I. Antibodies used in the study
Specificity dilution manufacturer clone
MDM2 1/50 Novocastra 1B10
P53 1/200 DAKO DO-7
P53 1/50 Novocastra PAb1801
Table II. Concordance of P53 stains
pab1081
do-7 negative poSitive
negative 377 22
positive 31 40
γ = 0.91
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The cases that were positive for P53 immunohis-
tochemistry using the PAb1081 antibody tended to 
be of a significantly higher grade, according to the 
standard system of stratification as well as the meth-
od proposed by Delahunt et al. (both p << 0.01). 
Remarkably, a sarcomatoid component was more fre-
quently observed in these same cases (p << 0.01). 
There was no relationship between P53 expression 
and pT stage. Interestingly, 2 out of 5 lymph node 
positive cases showed P53 expression when stained 
with PAb1081 (p < 0.05), but not when stained 
with DO-7. The tumors showing necrosis were more 
likely to be P53-positive with DO-7 (48%, p < 0.05) 
but not PAb1081. None of the above relationships 
were present for MDM2 staining. The immunopos-
itive and immunonegative tumors did not differ sig-
nificantly in their diameter, nor was a difference in 
patients’ age noted; however, MDM2-positive cases 
tended to be slightly larger, yet this was not a signif-
icant difference (6.4 vs. 6.1, p < 0.08).
Analysis of P53-positive, MDM2-positive cases 
showed similar tendencies to the ones shown above 
for P53-positive cases: double immunopositive tu-
mors were higher grade (both in the standard and 
Delahunt system) and were more likely to show 
sarcomatoid components, but they did not differ in 
their stage. Interestingly, PAb1081 P53-positive, 
MDM2-positive tumors were significantly larger 
than the rest of the tumors studied (7.6 cm vs. 6.1 
cm, p < 0.001); this difference was much less evi-
dent for DO-7 P53-positive, MDM2-positive cases 
(6.6 cm vs. 6.2 cm, non-significant).
Discussion
Renal cell carcinoma constitutes a heterogeneous 
group of diseases, differing in their genetics, mor-
phology and clinical features. The best established 
morphologic prognostic factors include tumor type 
and stage, presence of sarcomatoid components and 
for some subtypes, histologic grade [1]. The grading 
system for CCRCC has been revised recently [8], with 
necrosis being defined as an additional poor prognos-
tic factor. Therefore, the presence of necrosis has been 
proposed as an additional criterion for grading [9]. 
Although much effort has been made to identify fur-
ther prognostic biomarkers, so far they have been of 
little use in clinical practice [1, 10].
Inactivating mutations in the TP53 gene are fre-
quently observed in many human cancers, especially 
carcinomas. Its gene product participates in cell dam-
age sensing, proliferation and apoptosis, and is often 
referred to as the ‘guardian of the genome’. The role 
of TP53 mutations and their effects on protein ex-
pression in RCC have been studied for years, yet their 
prognostic role remains controversial. The TP53 mu-
tation rate in RCC is low [3]; nevertheless, a signifi-
cant proportion of cases express its protein product. 
Most of the studies analyzing P53’s role in RCC have 
been done using immunohistochemical methods of 
detection.
Girgin et al. observed P53 positivity in 20% of 
RCC cases studied; however, their study was limit-
Table III. Concordance of P53 and MDM2 positivity
mdm2
p53 negative poSitive
DO-7 negative 252 147
positive 40 31
γ = 0.14
PAb1081 negative 255 153
positive 37 25
γ = 0.06
Fig. 1. Strong positive nuclear reaction for P53 in clear cell 
renal cell carcinoma (DO-7 antibody). Immunohistochem-
istry, original magnification 400×
Fig. 2. Strong positive nuclear reaction for MDM2 in clear 
cell renal cell carcinoma. Immunohistochemistry, original 
magnification 400×
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ed to grade 3 and 4 cases only. A limitation to the 
Girgin et al. study was the lack of determination of 
mutation status of TP53 at the genetic level as only 
protein expression was studied. Furthermore, an older 
classification system was used during that study. Also, 
the cases with P53 expression showed significantly 
shorter survival, even in multivariate analysis [11]. 
Additionally, in a small series, Erdem et al. [12] found 
significant relationships between P53 expression, tu-
mor size, renal sinus invasion and Fuhrman grade. 
Conversely, Baytekin et al. observed a negative cor-
relation between P53 expression and both the grade 
and the stage of RCC tumors. Additionally, they were 
also unable to see any prognostic significance associ-
ated with this marker’s expression; indeed only stage 
appeared important for survival. However, it is im-
portant to note that this study only included a rela-
tively small and heterogeneous group of RCCs [13]. 
Similarly, Kramer et al. [14] also failed to show any 
prognostic significance associated with expression of 
P53 immunohistochemically. In additional multivari-
ate models, the stage was regarded as the only variable 
of importance. Likewise, these authors only analyzed 
a relatively small group of cases, composed not only 
of clear cell carcinomas but also of other subtypes. 
In a study by Shvarts et al. [15], P53 expression was 
strongly correlated with survival both in univariate 
and multivariate analysis. Further, it was indeed the 
only molecular predictor of survival in the discussed 
multivariate models. Interestingly, Kankuri et al. [16] 
observed no relationship between P53 expression 
and either the stage or metastatic spread. Moreover, 
P53-positive cases tended to be higher grade; howev-
er, this relationship was not significant. Interestingly, 
the significance of P53 expression in RCC may de-
pend on specific histologic type. Exemplified by Zi-
geuner et al. [17], the highest expression was found in 
papillary carcinoma (over 50% of cases) and lowest in 
CCRCC (12%) but only in the latter was it observed 
to significantly influence survival. This was seen both 
in univariate and multivariate analysis.
The MDM2 gene product participates in the very 
same pathway as TP53, although with an opposite 
function, as MDM2 is the main regulator of TP53 
functions and its expression is controlled by a P53-de-
pendent mechanism. Mutations of the MDM2 gene 
are seen in a minority of cancers, principally in sar-
comas. MDM2 amplification has been described as 
a mechanism of sarcomatoid transformation in RCC 
[18], but this is a rare phenomenon and does not ap-
pear to participate in earlier steps involved in carcino-
genesis. MDM2 is located at the 12q13 locus, which 
is frequently amplified in RCC and is related to poor 
prognosis [19]. It is important to note that MDM2 
presence is linked to poor prognosis; therefore this 
pathologic mechanism is not a result of gene loss, but 
its presence and functionality. However, most studies 
concerning MDM2 in RCC analyze its expression in 
the context of P53 expression.
The Liverpool group offered an interesting hypoth-
esis, showing that only a subset of RCCs expressing 
P53 fared worse, namely the cases in which MDM2 
was also expressed [4, 5, 20]. The frequency of such 
co-occurrence has been estimated at about 20% 
[19]. We decided to explore this idea, analyzing the 
P53 expression with two antibodies having different 
specificity as well as comparing P53/MDM2-positive 
and -negative cases with a number of other estab-
lished and potential prognostic factors. Moch et al., 
in an early report, observed a significant correlation 
between MDM2 and P53 expression; however, only 
P53 expression appeared to influence the progno-
sis [21]. Haitel et al. [22] discerned more frequent 
MDM2 as well as P53 expression in higher grade 
CCRCC. In their material there was no correlation 
between P53 and tumor stage; however, MDM2 ex-
pression was correlated with an increased amount of 
lymph node metastases. In univariate analysis, both 
markers were correlated with survival, yet on mul-
tivariate analysis, at first, only grade and stage were 
contributory. Furthermore, combined MDM2/P53 
expression improved the performance of the mod-
el. Uchida et al. found that expression of P53 alone, 
MDM2 alone, and P53/MDM2 co-expression was 
related to prognosis; however, MDM2 positivity was 
observed in less than 2% of cases studied while P53 
expression was present in 13% [23].
In conclusion, this study showed that P53 expres-
sion was correlated with known prognostic factors in-
cluding tumor diameter, grade, presence of sarcoma-
toid components and necrosis. We believe, however, 
that these results may have been influenced by the 
use of two separate P53 antibodies, each targeted at 
a different epitope. Lastly, the significance of MDM2 
expression appeared to be much lower in the context 
of this study.
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